专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015173430A2 EARLY PLACENTA INSULIN-LIKE PEPTIDE (PRO-EPIL) 审中-公开
标题翻译：早产儿胰岛素样肽（PRO-EPIL）
公开(公告)号：WO2015173430A2
公开(公告)日：2015-11-19
申请号：PCT/EP2015/060878
申请日：2015-05-18
申请人： CÉZANNE S.A.S.
发明人： DEMIRDJIAN, Gaïané , ESPINASSE, Delphine , BOURGOIN, Nicolas
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/471 , G01N2800/38 , G01N2800/387
摘要： The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification and/or therapy control of a prenatal disorder or condition in a pregnant female subject or the unborn fetus of said subject comprising the steps of: i) providing a sample of a bodily fluid of said subject; ii) determining the level of early placenta insulin-like peptide (pro-EPIL) or a fragment thereof in said sample; iii) comparing the determined level in the sample to a control level derived from subjects without said prenatal disorder or condition; wherein a deviation from said control level is indicative for said prenatal disorder or condition in said subject.
摘要翻译：本发明涉及一种用于诊断，预后，风险评估，风险分层和/或治疗所述受试者的怀孕女性受试者或未出胎胎儿的产前障碍或病症的方法，包括以下步骤：i）提供所述受试者的体液样品; ii）确定所述样品中早期胎盘胰岛素样肽（pro-EPIL）或其片段的水平; iii）将确定的样品水平与来自没有所述产前障碍或病症的受试者的对照水平进行比较; 其中与所述对照水平的偏差指示所述受试者中的所述产前障碍或病症。

2. 发明申请

WO2012028633A1 GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY 审中-公开
标题翻译：用于预测长期应对生长激素（GH）治疗的基因标记
公开(公告)号：WO2012028633A1
公开(公告)日：2012-03-08
申请号：PCT/EP2011/064951
申请日：2011-08-31
申请人： MERCK SERONO S.A. , CROTEAU, Pascal , RAELSON, John , WOJCIK, Jérôme , DESTENAVES, Benoit , OLIVIER, Clément , SCHNIEPER-SAMEC, Sonia
发明人： CROTEAU, Pascal , RAELSON, John , WOJCIK, Jérôme , DESTENAVES, Benoit , OLIVIER, Clément , SCHNIEPER-SAMEC, Sonia
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6876 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N2800/38 , G01N2800/52
摘要： The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
摘要翻译：本发明涉及遗传标记物用于鉴定生长激素缺乏（GHD）或特纳综合征（TS）患者中对生长激素治疗的应答以及治疗GHD或TS患者和用于基因分型的试剂盒的方法。

3. 发明申请

WO2010118330A3 USE OF TETRAHYDROBIOPTERIN AS A MARKER AND A THERAPEUTIC AGENT FOR FABRY DISEASE 审中-公开
标题翻译：四氢叶酸酯作为标记物和治疗药物用于制造疾病的使用
公开(公告)号：WO2010118330A3
公开(公告)日：2011-03-31
申请号：PCT/US2010030552
申请日：2010-04-09
申请人： BAYLOR RES INST , SCHIFFMANN RAPHAEL , BOTTIGLIERI TEODORO G , ARNING ERLAND , MOORE DAVID F
发明人： SCHIFFMANN RAPHAEL , BOTTIGLIERI TEODORO G , ARNING ERLAND , MOORE DAVID F
IPC分类号： A61K31/50 , A61K31/195 , A61K31/4985 , A61P3/00 , A61P9/00 , A61P43/00
CPC分类号： A61K31/4985 , G01N33/6893 , G01N2800/38 , Y10T436/147777
摘要： Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.
摘要翻译：代谢状态的血液和组织标志物，法布里病患者的健康并发症风险，以及遵循动物模型和包含四氢生物喋呤（BH4），BH4的前体和代谢物以及其他相关的法布里病患者的治疗效果的生物标志物协同因素在此被公开。本发明还描述了使用BH4治疗作为Fabry疾病的治疗选择，以预防，减缓或逆转法布里病的血管心脏和肾脏表现。

4. 发明申请

WO2010040234A1 METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS 审中-公开
标题翻译：分类和诊断分析方法
公开(公告)号：WO2010040234A1
公开(公告)日：2010-04-15
申请号：PCT/CA2009001453
申请日：2009-10-13
申请人： CHU SAINTE JUSTINE , MOREAU ALAIN , AKOUME NDONG MARIE-YVONNE
发明人： MOREAU ALAIN , AKOUME NDONG MARIE-YVONNE
IPC分类号： G01N33/567 , C12Q1/00 , G01N27/02
CPC分类号： G01N33/74 , G01N33/5008 , G01N33/566 , G01N33/6872 , G01N2333/4719 , G01N2333/726 , G01N2800/10 , G01N2800/38
摘要： Methods for diagnosing a predisposition to developing a scoliosis (e g, adolescent idiopathic scoliosis (AIS)) and identifying compounds for treating scoliosis based on the modulation of Gi protem-coupled receptor activity are described The methods involve measuring a change in impedance signals of cells expressing a receptor coupled to a Gi protein with a ligand To identify compounds useful in treatment, the cell is contacted with a test compound and a ligand If the impedance is higher in the presence of the test compound when compared to in the absence of the test compound, then the test compound is useful in treating the scoliosis.
摘要翻译：描述了用于诊断发展脊柱侧凸的倾向的方法（例如，青少年特发性脊柱侧凸（AIS））和基于Gi调节受体活性的调节来鉴定用于治疗脊柱侧凸的化合物。所述方法涉及测量表达的细胞的阻抗信号的变化用配体与Gi蛋白偶联的受体为了鉴定可用于治疗的化合物，细胞与测试化合物和配体接触如果在不存在测试化合物的情况下，当测试化合物存在时阻抗较高那么测试化合物可用于治疗脊柱侧凸。

5. 发明申请

WO2009126939A1 METHODS AND COMPOSITIONS FOR ALTERING BEHAVIOR ASSOCIATED WITH AUTISM SPECTRUM DISORDER 审中-公开
标题翻译：用于改变与光谱光谱相关的行为的方法和组合物
公开(公告)号：WO2009126939A1
公开(公告)日：2009-10-15
申请号：PCT/US2009/040282
申请日：2009-04-10
申请人： THE CHILDREN'S MERCY HOSPITAL , THE UNIVERSITY OF KANSAS , JACOBSON, Jill , ELLERBECK, Kathryn
发明人： JACOBSON, Jill , ELLERBECK, Kathryn
IPC分类号： G01N33/48
CPC分类号： G01N33/6893 , A61K38/11 , G01N2333/4719 , G01N2800/38
摘要： The present invention discloses methods for the diagnosis and treatment of autism. The diagnostic tools provided use analysis of levels of G-protein expression, oxytocin, and vasopressin. Treatment for autism spectrum disorder and symptoms of autism spectrum disorder, especially repetitive behavior, is also provided.
摘要翻译：本发明公开了用于诊断和治疗自闭症的方法。诊断工具提供了G蛋白表达水平，催产素和加压素水平的使用分析。还提供了自闭症谱系障碍和自闭症谱系障碍症状的治疗，特别是重复行为。

6. 发明申请

WO2008017871A1 BLOOD CELL SEPARATION 审中-公开
标题翻译：血细胞分离
公开(公告)号：WO2008017871A1
公开(公告)日：2008-02-14
申请号：PCT/GB2007/003066
申请日：2007-08-10
申请人： UNIVERSITY OF THE WEST OF ENGLAND, BRISTOL , AVENT, Neil, David , PLUMMER, Zoe, Eileen , HEAD, David, John
发明人： AVENT, Neil, David , PLUMMER, Zoe, Eileen , HEAD, David, John
IPC分类号： G01N33/50
CPC分类号： G01N33/6893 , G01N2800/38
摘要： There is provided a method of isolating foetal cells from an isolated sample of maternal blood, the method comprising identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell and selecting the identified cells, characterised in that the foetal marker is selected from: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EFlAl, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECRl -like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, Peroxiredoxin 2. There is also provided a method of cultivating foetal cells and a foetal cell isolation kit.
摘要翻译：提供了从分离的母体血液样品中分离胎儿细胞的方法，所述方法包括鉴定与相同母体细胞中的标记物的表达模式相比具有至少一种胎儿标记物的不同表达模式的细胞，并选择鉴定的细胞，其特征在于胎儿标记选自：HSP-60，单胺氧化酶，谷氨酰胺合酶，Ara-70，Ara-54，FLJ20202，DCN-1蛋白，RAB5A，HSP-7C，EF1A1，GRP78，MYL4， DnaJ同源亚族B族14，Vinculin，Desmoplakin，AMMECR1类蛋白，细胞外基质蛋白2前体蛋白，未表征蛋白Cxorf57，过氧化还原毒素1，过氧化还原毒素2.还提供了培养胎儿细胞和胎儿细胞分离试剂盒的方法。

7. 发明申请

WO2007042942A2 METHOD AND DEVICE TO RECOGNIZE NERVE INJURIES, SPECIFICALLY BRACHIAL PLEXUS INJURIES AND THEIR SEVERITY 审中-公开
标题翻译：识别神经损伤的方法和装置，特异性手术伤口及其严重程度
公开(公告)号：WO2007042942A2
公开(公告)日：2007-04-19
申请号：PCT/IB2006003854
申请日：2006-10-11
申请人： KORAK KLAUS J
发明人： KORAK KLAUS J
IPC分类号： C12Q1/527 , G01N33/68
CPC分类号： G01N33/6893 , G01N2800/28 , G01N2800/38 , G01N2800/40
摘要： The present invention relates to a method and a device to recognize nerve injuries, specifically brachial plexus injuries, and their severity, preferably of new born children. To achieve an inexpensive and quick test, which can be executed without harming the patient, it is proposed to measure the motor neuron loss by measuring a biochemical marker, i. e. NSE or protein S 100 in a body fluid.
摘要翻译：本发明涉及一种识别神经损伤，特别是臂丛神经损伤及其严重程度，优选新生儿的方法和装置。为了实现廉价且快速的测试，可以在不伤害患者的情况下执行，建议通过测量生物化学标记来测量运动神经元损失，即 NSE或蛋白质S 100在体液中。

8. 发明申请

WO98052593A1 METHOD FOR ASSISTING IN DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISTIC SYNDROMES 审中-公开
标题翻译：辅助诊断和治疗传统综合症的方法
公开(公告)号：WO98052593A1
公开(公告)日：1998-11-26
申请号：PCT/US1998/010224
申请日：1998-05-19
IPC分类号： A61K31/045 , A61K31/047 , A61K31/12 , A61K31/121 , A61K31/201 , A61K31/495 , A61K31/575 , A61K36/48 , A61K38/22 , A61K38/54 , A61K45/00 , A61P25/00 , G01N33/68 , G01N33/74 , A61K38/00 , A01N37/18 , A01N43/58 , A01N43/60 , A61K31/50 , A61K38/16 , A61K38/28 , A61K39/00 , A61K39/38 , G01N33/566
CPC分类号： G01N33/6893 , A61K31/045 , A61K31/047 , A61K31/12 , A61K31/121 , A61K31/201 , A61K31/495 , A61K31/575 , A61K36/48 , A61K36/484 , A61K38/2235 , G01N2333/645 , G01N2800/28 , G01N2800/38 , A61K2300/00
摘要： A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and/or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.
摘要翻译：公开了胰胆汁分泌与自闭症综合征之间的新颖关系。这种关系使得能够进行治疗自闭症综合征的症状的新疗法，其包括向具有自闭症综合征的个体施用治疗有效的，优选静脉内的剂量的促胰液素。该关系进一步使自闭症综合征的鉴别诊断，包括对个体血液和/或肠组织的分析以了解胰液素的存在以及分泌素水平与已知规范的比较。

9. 发明申请

WO2016090134A1 HAPTOGLOBIN AS A BIOMARKER FOR CEREBRAL PALSY IN NEWBORNS 审中-公开
标题翻译： HAPTOGLOBIN作为新西兰棕榈树的生物标记
公开(公告)号：WO2016090134A1
公开(公告)日：2016-06-09
申请号：PCT/US2015/063723
申请日：2015-12-03
申请人： RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPTIAL , OHIO STATE INNOVATION FOUNDATION
发明人： BUHIMSCHI, Catalin , BUHIMSCHI, Irina
IPC分类号： G01N33/53
CPC分类号： G01N33/721 , G01N33/6869 , G01N33/6893 , G01N2333/5412 , G01N2333/805 , G01N2800/38
摘要： A method of diagnosing a newborn as having an increased risk of developing cerebral palsy is described. The method includes obtaining a biological sample from the newborn; determining the level of Hp and/or HpRP in the biological sample and comparing it to a control value; determining the level of IL-6 in the biological sample and comparing it to a control value; and diagnosing the newborn as having an increased risk of developing cerebral palsy if the level of Hp and/or HpRP is lower than the control value, and the level of IL-6 is greater than the control value. Also described is a method of diagnosing a newborn as having an increased risk of developing retinopathy of prematurity.
摘要翻译：描述了诊断新生儿发展为脑瘫风险增加的方法。该方法包括从新生儿获得生物样品; 确定生物样品中的Hp和/或HpRP水平并将其与对照值进行比较; 确定生物样品中IL-6的水平，并将其与对照值进行比较; 并且如果Hp和/或HpRP的水平低于对照值，诊断新生儿具有发展为脑瘫的风险增加，并且IL-6的水平大于对照值。还描述了诊断新生儿具有增加早产儿视网膜病变风险的方法。

10. 发明申请

WO2015173430A3 EARLY PLACENTA INSULIN-LIKE PEPTIDE (PRO-EPIL) 审中-公开
标题翻译：早产儿胰岛素样肽（PRO-EPIL）
公开(公告)号：WO2015173430A3
公开(公告)日：2016-02-25
申请号：PCT/EP2015060878
申请日：2015-05-18
申请人： CÉZANNE S A S
发明人： DEMIRDJIAN GAÏANÉ , ESPINASSE DELPHINE , BOURGOIN NICOLAS
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/471 , G01N2800/38 , G01N2800/387
摘要： The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification and/or therapy control of a prenatal disorder or condition in a pregnant female subject or the unborn fetus of said subject comprising the steps of: i) providing a sample of a bodily fluid of said subject; ii) determining the level of early placenta insulin-like peptide (pro-EPIL) or a fragment thereof in said sample; iii) comparing the determined level in the sample to a control level derived from subjects without said prenatal disorder or condition; wherein a deviation from said control level is indicative for said prenatal disorder or condition in said subject.
摘要翻译：本发明涉及一种用于诊断，预后，风险评估，风险分层和/或治疗所述受试者的怀孕女性受试者或未出胎胎儿的产前障碍或病症的方法，包括以下步骤：i）提供所述受试者的体液样品; ii）确定所述样品中早期胎盘胰岛素样肽（pro-EPIL）或其片段的水平; iii）将确定的样品水平与来自没有所述产前障碍或病症的受试者的对照水平进行比较; 其中与所述对照水平的偏差指示所述受试者中的所述产前障碍或病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式